natgillin/translations-raw huggingface dataset:
The result was that patients given the combination lived for 11 months without their disease worsening, while those given Tafinlar alone lived for 8.8 months without their disease worsening.
Ugotovili so, da se je stanje bolnikov, ki so prejemali kombinacijo učinkovin, poslabšalo po enajstih mesecih, medtem ko se je pri tistih, ki so prejemali le zdravilo Tafinlar, stanje poslabšalo po 8,8 meseca.
The result with respect to the primary endpoint study are presented in Table 5.
Rezultati študije primarnega končnega stanja so povzeti v preglednici 5.
The resultant concentration is approximately 132 mg/mL (88 mg/mL of ceftolozane and 44 mg/mL of tazobactam).
Dobljena koncentracija je približno 132 mg/ml (88 mg/ml ceftolozana in 44 mg/ml tazobaktama).
The resulting complications (i.e. dyspnoea or even airway obstruction leading to, for instance, intubation or tracheotomy) should be anticipated.
Posledične zaplete (t.j. dispnea ali celo obstrukcija zračnih poti, zaradi katere je potrebna na primer intubacija ali traheotomija) moramo predvideti.
The resulting immature particles are non– infectious and are incapable of establishing new cycles of infection.
Nastanejo nezreli virusni delci, ki niso kužni in ne morejo začeti novega kroga okužbe.
The resulting reconstituted preparation of Myocet contains 50 mg of doxorubicin HCl/25 ml of concentrate for liposomal dispersion for infusion (2 mg/ml).
Končni rekonstituirani pripravek zdravila Myocet vsebuje 50 mg doksorubicinijevega klorida/25 ml koncentrata za liposomsko disperzijo za infundiranje (2 mg/ml).
The resulting solution contains 22 x 10 6 IU (1,300 µg) of aldesleukin per 1.2 mL.
Nastala raztopina vsebuje 22 x 106 i.e. (1.300 µg) aldeslevkina na 1,2 mL.
The resulting solution has a pH of 4.5-5.5 and is intended for intravenous use only.
Tako pripravljena raztopina ima pH 4,5 – 5,5 in je namenjena samo za intravensko uporabo.
The resulting solution is clear and ranges in colour from colourless to pale yellow without adversely affecting product quality.
Raztopina, ki jo dobite, je bistra, brezbarvna do rumena, barve v tem razponu ne vplivajo na kakovost zdravila. pH pripravljene raztopine je med 6,6 in 7,8.
The resulting solution is clear and ranges in colour from colourless to yellow or green-yellow without adversely affecting product quality.
Nastala raztopina je bistra, barve v razponu od brezbarvne do rumene ne vplivajo na kakovost izdelka.
The resulting solution is clear and ranges in colour from colourless to yellow or green-yellow without adversely affecting product quality.
Raztopina, ki jo dobite, je bistra, brezbarvna do rumena ali zeleno-rumena, barve v tem razponu ne vplivajo na kakovost zdravila. pH pripravljene raztopine je med 6,6 in 7,8.
The resulting solution is clear and ranges in colour from colourless to yellow or green-yellow without adversely affecting product quality.
Raztopina, ki jo dobite, je bistra, brezbarvna do rumena ali zeleno-rumena, barve v tem razponu ne vplivajo na kakovost zdravila. pH rekonstituirane raztopine je med 6,6 in 7,8.
The resulting solution should be administered over 60 minutes for all infusion volumes (50 ml, 100 ml or 250 ml).
Nastalo raztopino vseh infuzijskih volumnov (50 ml, 100 ml ali 250 ml) je treba aplicirati 60 minut.
The resulting solution should be clear to slightly opalescent, colourless to slightly yellow.
Nastala raztopina mora biti bistra do rahlo opalescentna, brezbarvna do rumenkasta.
The resulting solution should be clear, without particulate matter.
Nastala raztopina mora biti bistra in brez delcev.
The resulting solution should be shaken prior to being transferred to an infusion bag or bottle containing either sodium chloride 9 mg/ml (0.9%) solution for injection, dextrose 50 mg/ml (5%) solution for injection, sodium chloride 4.5 mg/ml and dextrose 25 mg/ml solution for injection (0.45% sodium chloride and 2.5% dextrose) or Lactated Ringer’s solution.
Nastalo raztopino je treba pretresti, preden se jo prenese v infuzijsko vrečko ali steklenico, ki vsebuje natrijev klorid 9 mg/ml (0,9 %) raztopino za injiciranje, glukozo 50 mg/ml (5 %) raztopino za injiciranje, natrijev klorid 4,5 mg/ml in glukozo 25 mg/ml raztopino za injiciranje (0,45 % natrijev klorid in 2,5 % glukoza) ali raztopino Ringerjevega laktata.
The resulting ‘emulsion’ is then injected.
Tako dobljena „emulzija“ se nato injicira.
The resulting ‘emulsion’ will then be injected.
Tako dobljena „emulzija“ se nato injicira.
The results are summarised in the table below.
Rezultati so povzeti v tabeli spodaj.
The results demonstrated that 4 mg zoledronic acid showed comparable efficacy to 90 mg pamidronate in the prevention of SREs.
Rezultati so pokazali, da je 4 mg zoledronske kisline preprečilo SRE podobno učinkovito kot 90 mg pamidronata.
The results for clinically relevant responders pooled from two flexible dose studies out of the three pivotal 26-week multicentre studies in patients with mild-to-moderately severe Alzheimer’s Dementia, are provided in Table 4 below.
Rezultate bolnikov, ki so se klinično pomembno odzvali na zdravljenje, združene iz dveh študij prilagojenih odmerkov od treh ključnih 26-tedenskih multicentričnih študij pri bolnikih z blago do zmerno težko Alzheimerjevo demenco, podaja spodnja preglednica 4.
The results for clinically relevant secondary endpoints are shown in Table 2.
Rezultate za klinično pomembne sekundarne cilje študije kaže preglednica 2.
The results for the 40 mg every other week dose are summarised in Table 6.
Rezultati odmerka 40 mg vsak drugi teden so strnjeni v preglednici 6.
The results for the higher dose combination of umeclidinium bromide and vilanterol did not consistently show relevant improvements in lung function.
Rezultati kombinacije z višjimi odmerki umeklidinijevega bromida in vilanterola niso dosledno prikazali bistvenih izboljšanj pri delovanju pljuč.
The results for the primary endpoint in the modified intent to treat (m-ITT) populations (defined as all randomised patients who received at least one dose of the study treatment, with the exclusion of those patients lost to follow up for unknown reasons) were as follows:
Rezultati primarnega končnega opazovanega dogodka za modificirane populacije z namenom zdravljenja (m-ITT – modified Intent to Treat) (opredeljene kot vsi randomizirani bolniki, ki so prejeli vsaj en odmerek študijskega zdravila, brez bolnikov, ki so bili izgubljeni za spremljanje zaradi neznanega razloga), so bili naslednji:
The results from Studies II, III, and VI are shown in Table 6.
Rezultati iz študij II, III in VI so prikazani v preglednici 6.
The results from study SC-I is shown in Table 5.
Rezultati iz študije SC-I so prikazani v preglednici 5.
The results from the TOPIC study confirmed the efficacy of teriflunomide in RRMS (including early RRMS with first clinical demyelinating event and MRI lesions disseminated in time and space).
Rezultati študije TOPIC so potrdili učinkovitost teriflunomida pri recidivno-remitentni multipli sklerozi (vključno z zgodnjo recidivno- remitentno multiplo sklerozo s prvim kliničnim demielinizirajočim dogodkom ter časovno in po legi diseminiranimi MR-spremembami).
The results from the trial were not consistent in the subgroup of patients with a poor performance status (WHO PS = 2, n = 70), where overall survival and time to progression were similar in both arms.
Rezultati študije niso skladni pri podskupini s slabim odzivom (WHO PS = 2, n = 70), čas skupnega preživetja in napredovanje bolezni pa je podobno v obeh primerih.
The results from the trial were not consistent in the subgroup of patients with a poor performance status (WHO PS=2, n=70), where overall survival and time to progression were similar in both arms.
Rezultati preskušanja niso bili dosledni v podskupini bolnikov s slabo telesno zmogljivostjo (TZ po merilih Svetovne zdravstvene organizacije = 2, n = 70), kjer sta bila skupno preživetje in čas do napredovanja bolezni podobna v obeh krakih.
The results from the trial were not consistent in the subgroup of patients with a poor performance status (WHO PS=2, n=70), where overall survival and time to progression were similar in both arms.
Rezultati študije niso skladni pri podskupini s slabim odzivom (WHO PS=2, n=70), čas skupnega preživetja in napredovanje bolezni pa sta podobna v obeh primerih.
The results in the AI subgroup are inconclusive. b OS is presented for the final survival analyses at 75% maturity. c Nominal p-value with no adjustments made for multiplicity between the initial overall survival analyses at 50% maturity and the updated survival analyses at 75% maturity. d ORR was assessed in patients who were evaluable for response at baseline (i.e. those with measurable disease at baseline: 240 patients in the Faslodex 500 mg group and 261 patients in the Faslodex 250 mg group). e Patients with a best objective response of complete response, partial response or stable disease ≥24 weeks.
Na podlagi rezultatov pri AI podskupini ni možno narediti zaključkov. b Celotno preživetje je predstavljeno za končne analize preživetja ob 75 % dospelosti. c Nominalna p vrednost brez korekcije za večkratne primerjave med uvodnimi analizami celokupnega preživetja ob 50 % dospelosti in posodobljenimi analizami preživetja pri 75 % dospelosti. d ORR je bila ocenjena pri bolnikih, katerih odgovor je bil ovrednoten na izhodišču (tj. tisti z merljivo boleznijo na začetku raziskave: 240 bolnikov v skupini Faslodex 500 mg in 261 bolnikov v skupini Faslodex 250 mg). e Bolniki z najboljšim objektivnim odzivom celotnega odziva, delni odziv ali stabilna bolezen ≥ 24 tednov.
The results indicate that a somewhat higher plasma concentration can be expected with OPATANOL in this population.
Izsledki te študije kažejo, da lahko pri tej populaciji bolnikov pričakujemo nekoliko višje plazemske koncentracije zdravila OPATANOL.
The results indicate that patients whose HIV expressed 3 or more thymidine-analogue associated mutations (TAMs) that included either the M41L or L210W reverse transcriptase mutation showed reduced response to tenofovir disoproxil 245 mg (as fumarate) therapy.
Rezultati so pokazali, da so bolniki, katerih HIV je izražal tri ali več mutacij, povezanih z analogom timidina (TAM, thymidine-analogue associated mutations), ki so vsebovale ali M41L ali L210W mutacijo reverzne transkriptaze, kazali zmanjšan odziv na zdravljenje z 245 mg dizoproksiltenofovirata (v obliki dizoproksiltenofovirijevega fumarata).
The results obtained in populations with different characteristics (e.g. unstable angina or non-Q-wave MI, low to high risk levels, diabetes, need for revascularisation, age, gender, etc.) were consistent with the results of the primary analysis.
Rezultati, pridobljeni pri populacijah z različnimi karakteristikami (npr. nestabilna angina, MI brez Q- zobca, veliko do majhno tveganje, sladkorna bolezen, potreba po revaskularizaciji, spol, starost, itd.), so skladni z rezultati primarne analize.
The results obtained in populations with different characteristics (e.g. unstable angina or non-Q-wave MI, low to high risk levels, diabetes, need for revascularisation, age, gender, etc.) were consistent with the results of the primary analysis.
Rezultati, pridobljeni pri populacijah z različnimi karakteristikami (npr. nestabilna angina, MI brez Q- zobca, visoka do nizka raven tveganja, diabetes, potreba po revaskularizaciji, spol, starost, itd), so skladni z rezultati primarne analize.
The results of a population pharmacokinetic analysis of these trials have demonstrated that paediatric patients with body weights 40 kg have a reduced systemic exposure (measured by Css) of A771726 relative to adult rheumatoid arthritis patients (see section 4.2).
Rezultati populacijske farmakokinetične analize teh preskušanj so pokazali, da je pri pediatričnih bolnikih s telesno maso  40 kg sistemska izpostavljenost A771726 (merjena s Css) manjša kot pri odraslih bolnikih z revmatoidnim artritisom (glejte poglavje 4.2).
The results of a population pharmacokinetic analysis of these trials have demonstrated that pediatric patients with body weights ≤40 kg have a reduced systemic exposure (measured by Css) of A771726 relative to adult rheumatoid arthritis patients (see section 4.2).
Rezultati populacijske farmakokinetične analize teh preskušanj so pokazali, da je pri pediatričnih bolnikih s telesno maso 40 kg sistemska izpostavljenost A771726 (merjena s Css) manjša kot pri odraslih bolnikih z revmatoidnim artritisom (glejte poglavje 4.2).
The results of a single-dose study showed that in young adult volunteers, retigabine Cmax was approximately 65% higher in females than in males, and in elderly volunteers (66 to 82 years of age), retigabine Cmax was approximately 75% higher in females compared with males.
Rezultati študije enega odmerka so pokazali, da je Cmax retigabina pri mladih odraslih prostovoljcih približno 65 % večja pri ženskah kot pri moških ter pri starejših prostovoljcih (starih od 66 do 82 let) približno 75 % večja pri ženskah kot pri moških.
The results of acute and subacute toxicity studies performed in monkeys suggested that intrathecal DepoCyte was tolerated up to a dose of 10 mg (comparable to a human dose of 100 mg).
Rezultati raziskav akutne in subakutne toksičnosti, ki so jih opravili na opicah, kažejo na to, da so zdravilo DepoCyte prenašale do intratekalnega odmerka 10 mg (primerljivo z odmerkom 100 mg pri človeku).
The results of analysis of the primary efficacy endpoint, the estimated proportion of patients experiencing impending relapse by end of Week 26 of the Double-blind, Active-controlled Phase, showed that Abilify Maintena 400 mg/300 mg is non-inferior to aripiprazole oral tablets 10-30 mg.
Rezultati analize primarne končne točke učinkovitosti in ocenjeno razmerje bolnikov, pri katerih se do konca 26. tedna dvojno slepe aktivno nadzorovane faze pojavijo znaki bližnjega relapsa bolezni, kažejo, da je zdravilo Abilify Maintena 400 mg/300 mg neinferiorno zdravilu aripiprazol v 10–30 mg peroralnih tabletah.
The results of bioequivalence studies in healthy subjects demonstrated that Synjardy (empagliflozin/metformin hydrochloride) 5 mg/850 mg, 5 mg/1,000 mg, 12.5 mg/850 mg, and
Rezultati bioekvivalenčnih študij pri zdravih prostovoljcih so pokazali, da so kombinirane tablete zdravila Synjardy (empagliflozin/metforminijev klorid) 5 mg/850 mg, 5 mg/1.000 mg,
the results of blood tests before and during treatment how well your body responds to the medicine.
izvidov krvnih preiskav, opravljenih pred zdravljenjem in med njim; odziva vašega telesa na zdravilo.
the results of blood tests carried out before and during treatment how well you tolerate treatment.
izvidov krvnih preiskav, opravljenih pred začetkom zdravljenja in med zdravljenjem, od vašega prenašanja zdravila.
the results of blood tests carried out before and during treatment, how well you tolerate treatment.
izvidov preiskav krvi, opravljenih pred zdravljenjem in med njim, tega, kako dobro prenašate zdravljenje.
the results of blood tests carried out before treatment
izvide krvnih preiskav, opravljenih pred zdravljenjem,
the results of blood tests carried out before treatment
izvidov krvnih preiskav, opravljenih pred začetkom zdravljenja.
the results of blood tests carried out before treatment
izvidov krvnih preiskav, opravljenih pred začetkom zdravljenja;
The results of study NV15942 provide the rationale for recommending treatment regimens based on genotype, baseline viral load and virological response at week 4 (see Tables 1, 13 and 14).
Rezultati študije NV15942 predstavljajo osnovo za priporočila za zdravljenje v odvisnosti od genotipa, virusnega bremena pred začetkom zdravljenja in virološkega odziva v 4. tednu (glejte preglednice 1, 13 in 14).
The results of summary of PID at 60 minutes (SPID0-60) showed that all strengths of Instanyl had significantly higher mean SPID0-60 scores compared with placebo (p0.001) demonstrating better pain relief of Instanyl compared to placebo during 60 minutes.
Skupni rezultati PID po 60 minutah (SPID0-60) so pokazali, da so imele vse jakosti zdravila Instanyl pomembno višje vrednosti SPID0-60 v primerjavi s placebom (p < 0,001), kar pomeni, da zdravilo Instanyl v 60 minutah učinkoviteje lajša bolečino od placeba.
The results of the additional studies supported the use of Mimpara for hypercalcaemia in patients with primary hyperparathyroidism.
Rezultati dodatnih študij so podprli uporabo zdravila Mimpara pri zdravljenju hiperkalciemije pri bolnikih s primarnim hiperparatiroidizmom.
The results of the Intent-To-Treat (ITT) population for the primary efficacy outcome are shown below:
Rezultati vključenih bolnikov (ITT – Intent-To-Treat) glede glavnega merila učinkovitosti so prikazani spodaj:
The results of the interim analysis and the updated analysis also showed a significant improvement in all main secondary endpoints in the Xofigo arm compared to the placebo arm (see Table 3).
Izsledki vmesne analize in posodobljene analize so pokazali znatno izboljšanje v vseh glavnih sekundarnih opazovanih dogodkov v skupini, ki je prejemala zdravilo Xofigo, v primerjavi s skupino, ki je prejemala placebo (glejte preglednico 3).
The results of the main efficacy analyses are summarised in the table below:
Rezultati glavnih analiz učinkovitosti so povzeti v spodnji tabeli:
The results of the PK/PD analyses in Phase II and III were consistent with the data established in healthy subjects.
Izsledki PK/PD analiz iz kliničnih preskušanj II. in III. faze so skladni z izsledki, ki so jih ugotovili pri zdravih osebah.
The results of the primary analysis were confirmed with longer follow-up (median observation time: 48 months) and have been added to Table 4 to show the comparison between the 25 and 48 month follow-up periods.
Rezultate primarne analize je potrdilo daljše spremljanje (mediana časa opazovanja: 48 mesecev), ki je dodano preglednici 4 in prikazuje primerjavo med 25- in 48-tedenskim spremljanjem.
The results of the primary and secondary composite efficacy endpoints, and the results of all the individual components of the composite endpoints are shown in Figure 1.
Slika 1 prikazuje rezultate primarnega in sekundarnih sestavljenih opazovanih dogodkov učinkovitosti in rezultate vseh posameznih sestavin sestavljenih opazovanih dogodkov.
The results of the primary endpoint, the rate of change in TKV for subjects randomised to tolvaptan (normalised as percentage) to the rate of change for subjects on placebo, were highly statistically significant.
Rezultati primernega opazovanega dogodka, stopnje spremembe TKV za osebe, randomizirane za tolvaptan (normalizirano v obliki odstotka), glede na stopnjo spremembe za osebe na placebu, so bili statistično izjemno značilni.
The results of the randomised and blinded second treatment course are presented in table 6.
Rezultati randomiziranega in slepega drugega cikla zdravljenja so predstavljeni v preglednici 6.
The results of the safety studies indicated that the product is safe for chickens and ducks.
Rezultati študij o varnosti so pokazali, da je izdelek varen za piščance in race.
The results of the safety studies indicated that the product is safe for chickens.
Rezultati raziskav o varnosti so pokazali, da je izdelek varen za piščance.
The results of the second study were insufficient to prove the long- term effectiveness of Sifrol.
Rezultati druge študije niso bili zadostni, da bi dokazali dolgoročno učinkovitost zdravila Sifrol.
The results of the studies presented showed that the thiomersal-free vaccines produced protective levels of antibodies against hepatitis B virus to a similar extent to the vaccines that contained thiomersal at the end of the vaccination course.
Rezultati predstavljenih študij so pokazali, da so cepiva, ki niso vsebovala tiomersala, povzročila nastanek zaščitne ravni protiteles proti virusu hepatitisa B, ki so bile na koncu cikla cepljenja podobne ravnem pri cepivih, ki so vsebovala tiomersal.
The results of the studies showed that dogs with congestive heart failure caused by faulty heart valves that were given PRILACTONE tablets in addition to another heart medicine (‘standard therapy’), had a longer survival time than the dogs that received the standard therapy plus placebo tablets.
Rezultati študij so pokazali, da so psi s kongestivno odpovedjo srca zaradi okvarjenih srčnih zaklopk, ki so prejemali tablete zdravila PRILACTONE istočasno z drugim zdravilom za srce („standardno zdravljenje“), imeli daljši čas preživetja kot psi, ki so prejemali standardno zdravljenje in tablete placeba.
The results of the study indicate no increased risk of serious infection, serious arrhythmia, or death in children with HSCHD associated with Synagis prophylaxis compared with children who did not receive prophylaxis
Rezultati raziskave ne nakazujejo povečanega tveganja za resne okužbe, resne aritmije ali smrt pri otrocih s HSCHD v povezavi s profilakso z zdravilom Synagis v primerjavi z otroci, ki niso prejeli profilakse.
The results of the study showed no difference in efficacy between Resolor and placebo with response rates of 17% and 17.8% respectively (P= 0.9002).
Rezultati študije niso pokazali razlike v učinkovitosti med zdravilom Resolor in placebom – odziv je bil pri prukalopridu 17 % in pri placebu 17,8 % (p = 0,9002).
The results of the study showed no difference in efficacy between Resolor and placebo with response rates of 17% and 17.8% respectively (P= 0.9002).
Rezultati študije niso pokazali razlike v učinkovitosti med zdravilom Resolor in placebom – odziv je bil pri zdravilu Resolor 17 % in pri placebu 17,8 % (p = 0,9002).
The results of the two studies taken together showed that, on average, it took 48.3 weeks for the disease to get worse in patients taking Revlimid, compared with 20.1 weeks in those taking placebo.
Združeni rezultati obeh študij so pokazali, da je v povprečju trajalo 48,3 tedna, da se je bolezen poslabšala pri bolnikih, ki so jemali Revlimid, v primerjavi z 20,1 tedna pri bolnikih, ki so prejemali placebo.
The results of these analyses of efficacy are summarised in the table below:
Analiza učinkovitosti z uporabo PK populacije je skladna z analizo NZ populacije in podpira prednost AC proti GC.
The results of this heterologous challenge study indicate 80.7%-100% protection in all adjuvanted candidate vaccines compared to 43% protection with the non adjuvanted vaccine, showing the benefit of AS03 adjuvantation.
Rezultati te heterologne provokacijske študije kažejo od 80,7% do 100% zaščito pri vseh kandidatnih cepivih z adjuvansom, v primerjavi s 43-odstotno zaščito pri cepivih brez adjuvansa, kar kaže na korist adjuvansa AS03.
The results of this multicentre, double-blind, randomised trial showed that tacrolimus ointment, 0.03% and 0.1%, is significantly more effective (p<0.001 for both) than 1% hydrocortisone acetate ointment (Table 2).
Rezultati te multicentrične, dvojno slepe randomizirane raziskave so pokazali, da je mazilo s takrolimusom (tako 0,03% kot 0,1%) značilno učinkovitejše (p<0,001 za oba) kot 1% mazilo s hidrokortizonacetatom (preglednica 2).
The results of this retrospective subgroup analysis should be viewed with caution because of the small sample size and potential differences of the sub-study population relative to the overall trial population.
Rezultate retrospektivne analize v tej podskupini je treba previdno tolmačiti zaradi majhne velikosti vzorca in morebitnih razlik te populacije glede na celotno populacijo iz preskušanja.
The results of this study demonstrated that sunitinib had an effect on QTc interval (defined as a mean placebo-adjusted change of >10 msec with a 90% CI upper limit >15 msec) at therapeutic concentration (Day 3) using the within-day baseline correction method, and at greater than therapeutic concentration (Day 9) using both baseline correction methods.
Rezultati te študije so pokazali, da sunitinib vpliva na interval QTc (opredeljeno kot povprečna, glede na placebo korigirana sprememba za > 10 milisekund in z zgornjo mejo 90 % intervala zaupanja > 15 milisekund); vpliv se je izkazal pri terapevtski koncentraciji (3. dan) z uporabo znotrajdnevnega postopka korekcije glede na izhodišče ter v več kot terapevtski koncentraciji (9. dan) z uporabo obeh postopkov korekcije glede na izhodišče.